期刊介绍：

Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.


The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. 


Cancer Biotherapy and Radiopharmaceuticals coverage includes:
Antibody drug conjugates
Fusion toxins and immunotoxins
Nanoparticle therapy
Vascular therapy
Inhibitors of proliferation signaling pathways

Cancer Biotherapy and Radiopharmaceuticals is under the editorial leadership of Editors Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham; Robert K. Oldham, MD, Lower Keys Cancer Center; and other leading investigators. View the entire editorial